New Benchmarks on Protocol Amendment Experience in Oncology Clinical Trials
Therapeutic Innovation & Regulatory Science · 2024
DOI: 10.1007/s43441-024-00629-2 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Therapeutic Innovation & Regulatory Science, 2024. Verfasst von Emily Botto und 2 weiteren Autor:innen. Beteiligte Einrichtung: Tufts University School of Medicine, 145 Harrison Ave, Boston, MA, 02111, USA. Emily.botto@tufts.edu. Hauptthemen laut MEDLINE: Clinical Trials as Topic, Benchmarking. Die Arbeit nennt 21 Literaturangaben. Gefördert von: Gilead Sciences, Biogen Idec, EMD Serono.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Tufts University School of Medicine, 145 Harrison Ave, Boston, MA, 02111, USA. Emily.botto@tufts.edu.
- Tufts University School of Medicine, 145 Harrison Ave, Boston, MA, 02111, USA.
ORCID-Profile: Emily Botto
Förderung
- Gilead Sciences
- Biogen Idec
- EMD Serono
- Amgen
- Merck
- Eli Lilly and Company
- AstraZeneca
- Regeneron Pharmaceuticals
Zitieren
APA
Botto, E., Smith, Z., & Getz, K. (2024). New Benchmarks on Protocol Amendment Experience in Oncology Clinical Trials. Therapeutic Innovation & Regulatory Science. https://doi.org/10.1007/s43441-024-00629-2
Vancouver
Botto E, Smith Z, Getz K. New Benchmarks on Protocol Amendment Experience in Oncology Clinical Trials. Therapeutic Innovation & Regulatory Science. 2024. doi:10.1007/s43441-024-00629-2
BibTeX
@article{Botto2024,
author = {Botto, Emily and Smith, Zachary and Getz, Kenneth},
title = {New Benchmarks on Protocol Amendment Experience in Oncology Clinical Trials},
journal = {Therapeutic Innovation & Regulatory Science},
year = {2024},
doi = {10.1007/s43441-024-00629-2}
}
EUVIMED